ArticlePloS one2026
Epidemiology and antimicrobial resistance of Enterobacteriaceae causing community-acquired urinary tract infections in Tétouan, Morocco (2022-2023).
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUrinary tract infections (UTIs) are among the most common community-acquired bacterial infections and Enterobacteriaceae are the leading etiological agents. Rising antimicrobial resistance (AMR) within this family poses major challenges for empirical treatment. This study aimed to describe the species distribution and antimicrobial resistance patterns of uropathogenic Enterobacteriaceae isolated from outpatients in Tétouan, Morocco.
methodsA cross-sectional descriptive study was conducted between April 2022 and December 2023 in three medical laboratories. Enterobacteriaceae isolated from urine cultures with significant bacteriuria were identified using the VITEK®2 system. Antimicrobial susceptibility testing was performed according to EUCAST 2021 guidelines. Extended-spectrum β-lactamase (ESBL) production was assessed using the Modified Double Disc Synergy Test (MDDST). Statistical analyses were performed using SPSS version 26, with significance set at p < 0.05.
resultsA total of 422 Enterobacteriaceae isolates were obtained, predominantly from female patients (74.9%). Escherichia coli was the most frequent species (83.4%), followed by Klebsiella pneumoniae (9.2%). High resistance rates were observed for ampicillin (60.9%) and ticarcillin (56.2%), while resistance to imipenem (1.2%) and ertapenem (0.9%) remained low. ESBL production was detected in 20 isolates (4.7%), with E. coli being the predominant ESBL-producing species (16/20; 80.0%), while K. pneumoniae exhibited a higher species-specific prevalence (4/39; 10.3%). Male patients exhibited significantly higher resistance to several β-lactams, while pediatric patients showed higher resistance to cephalosporins and aminoglycosides.
conclusionUropathogenic Enterobacteriaceae circulating in the community of Tétouan exhibit substantial resistance to commonly prescribed oral antibiotics, although carbapenems remain highly effective. The moderate prevalence of ESBL-producing strains highlights the need for reinforced antimicrobial stewardship and continuous regional surveillance to guide empirical treatment and limit the spread of resistant pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.